Researchers found curcumin suppresses the inflammatory response that induces metastasis, causing cell death and reversing disease progression. Curcumin breaks down chemotherapy doses, making it less toxic while maintaining efficacy, offering new hope for breast cancer treatment.
Researchers found that enzyme EZH2 has two forms, one promoting oncogenesis and the other inhibiting cell growth. This discovery offers new insights into the role of EZH2 in cancer development and potentially leads to more effective treatments.
Hassall's corpuscles produce chemical signals that instruct dendritic cells to develop regulatory T cells, which patrol the body for 'bad' T cells. This discovery opens new avenues for exploring regulatory T cells in autoimmune disease and cancer.
Researchers have discovered a novel T helper cell type, called THi cells, that produce the potent cytokine IL-17 and are responsible for initiating chronic inflammation and autoimmunity. The study's findings suggest that targeting these cells could lead to effective treatments for inflammatory diseases such as arthritis and asthma.
A study of 526 prostate cancer patients suggests that a man's body mass at different ages and adult weight gain can predict the risk of progression after surgery. Researchers found that obese men and those who gained weight quickly experienced biochemical failure more often.
A large US population study found that eating foods with phytoestrogens, such as soy and fruits, may lower lung cancer risk. The study, involving over 3,500 participants, discovered a 46% reduced risk of developing lung cancer among those who consumed the highest amount of phytoestrogen-rich foods.
A study found that two-thirds of Phase I abstracts accepted by the American Society of Clinical Oncology were published in peer-reviewed medical journals within seven and a half years. The median time to publication was 3.4 years, which is concerning as it may delay further investigation with encouraging agents.
Researchers discovered a potential biomarker, PKCi, which predicts outcome in non-serous ovarian cancer when combined with Cyclin E. High levels of the protein correspond to reduced survival rates.
Researchers have found that few B cells are needed to trigger an effective T-cell immune response in certain cancers. A personalized vaccine used in a Phase I study resulted in an impressive 89% survival rate for patients with mantle cell lymphoma. The study paves the way for future vaccine use in other hematological cancers.
Researchers found that breast cancer detected by mammography has a substantially better survival prognosis, even after adjusting for stage of disease and tumor characteristics. The study suggests that this is due to the detection of slower-growing tumors, which are more likely to be node-negative.
A gene called TRPS-1 is over-expressed in 90% of breast cancers, making it a potential target for cancer vaccines. Researchers are exploring its role and developing immunotherapy approaches to treat breast cancer.
Scientists have found that the hepatitis B virus primes liver cells to turn cancerous by 'turning off' an enzyme called GSK-3ß, which normally suppresses tumor formation. This discovery has potential relevance for other cancers and could lead to novel therapeutic approaches, including gene therapy and small molecules.
Researchers at the University of Texas M. D. Anderson Cancer Center discovered that curcumin stops laboratory strains of melanoma from proliferating by shutting down nuclear factor-kappa B (NF-kB). The spice also induces apoptosis, or programmed death, in cancer cells.
A study published in PNAS found that prenatal exposure to diethylstilbestrol (DES) can permanently alter tissue in rats, making them more susceptible to hormone-dependent tumors. The researchers believe this phenomenon could explain why some people with inherited tumor suppressor gene defects develop cancer while others do not.
Researchers found a potential link between testicular cancer and male infertility, suggesting that genetic mutations during fetal development may play a role. The study provides insights into the origins of human testicular cancer, which is a leading cause of cancer in men between 15-39 years old.
Researchers used RNAi to silence STAT3 in mouse breast cancer cells, finding a 75% reduction in protein expression. This reduced the ability of cancer cells to invade normal tissues, offering new insights into cancer metastasis.
Researchers developed a genetic blueprint that predicts response to two chemotherapy drugs and/or radiation therapy in esophageal cancer patients. The study found six gene variants associated with improved survival rates, with certain combinations more effective than others.
Researchers discover CML's unique cell death protein, lipocalin 24p3, that destroys healthy bone marrow cells, allowing leukemia to grow and spread. Blocking this protein with an antibody may prove useful in treating CML patients when combined with traditional treatment.
Researchers have reported encouraging results with the novel drug AMN107, which is showing an increasingly strong benefit as doses are raised. Over 90% of patients with earlier stage Chronic Myeloid Leukemia (CML) have achieved a hematologic response, and over 70% of those in advanced stages have also benefited.
A study of 301 patients with glioblastoma multiforme found that the 'SS' variant genotype of hTERT significantly improved survival rates, averaging 25 months compared to 14 months for other genotypes. The research suggests new treatment directions for this aggressive cancer.
Researchers developed a test to measure CDK activity, which accurately predicts tumor response to Tarceva. A second study found that increased CDK activity correlates with sensitivity to Taxol, providing preclinical evidence for developing a novel device to measure CDK activity in human tissue.
Researchers discovered that shape-altering genes, known for their role in embryonic development, direct ovarian cancer cells to take on various forms. These unique shapes make each form of ovarian cancer distinct from one another and the surface epithelium.
Researchers found that combining chemotherapy with Herceptin before surgery in early-stage breast cancer patients resulted in a 42% higher tumor reduction and 66.7% pathological complete remission rate compared to chemotherapy alone. The combination also showed less risk of heart damage, leading the clinical trial to be halted early.
A recent study found that advancements in radiation techniques have greatly reduced the risk of cardiac death after radiation therapy for breast cancer. Women with left-sided breast cancer had a higher mortality rate from ischemic heart disease compared to those with right-sided breast cancer, but this difference decreased over time.
A new test, NMP22 tumor marker assay, has been shown to be three times more effective than a traditional laboratory test in detecting bladder cancer. The test can detect the disease in patients with blood in their urine and certain risk factors, such as smoking and exposure to chemicals.
Researchers confirm Vioxx increased cardiovascular risk by nearly doubling events, including heart attacks and strokes, in patients with recurrent colon polyps. The trial was stopped early due to safety concerns.
A study found that the experimental test's effectiveness was undermined by technical issues and biological implausibility, casting doubt on its potential as a reliable diagnostic tool. The researchers emphasize the need for standardized protocols in proteomics research to ensure reproducibility of results.
Researchers found that women with primary hypothyroidism had a 61 percent lower risk of developing invasive breast cancer and those newly diagnosed were 57 percent less likely to have the condition. Women with both conditions tended to be older when diagnosed with a less aggressive, indolent disease.
Researchers have discovered a new gene cluster, Rhox genes, selectively expressed in male and female reproductive tissues in adult mice. The cluster's unique expression pattern suggests its role in regulating reproduction and potentially developing new contraceptive methods.
A new gene vaccine has shown high efficacy in protecting mice against Her2/neu breast cancer, using a viral-vectored approach to stimulate a long-lasting immune response. The vaccine protected 86% of experimental mice from developing the disease.
Researchers found women with invasive lobular carcinoma have a different disease type, benefiting from tailored treatment approaches. Alternative therapies like hormonal treatments may be more effective for this rare form of breast cancer.
The study found that a protein complex called INO80 plays a crucial role in loosening histone grip on DNA, allowing DNA repair machinery to access damaged areas. The researchers discovered a specific form of histone protein, gamma-H2AX, acts as a code directing DNA repair proteins to breaks.
Researchers found that a protein called STAT3 is crucial for the development of psoriasis and can be reversed with a specific treatment. The study's findings offer a potential new target for medications to relieve symptoms of psoriasis.
The phosphatidylinositol 3 kinase (PI3K) pathway is crucial in breast cancer development, with aberrant levels and mutations affecting critical growth factor receptors. Researchers believe targeting central nodes in this pathway can effectively treat the disease.
Researchers found that celecoxib reduced estrogen receptor expression by an average of 9% after six months of treatment. This finding confirms celecoxib's antiproliferative properties and suggests a new potential therapeutic approach for breast cancer prevention.
A recent re-analysis of large clinical trials found that chemotherapy significantly improves survival rates in patients with ER-negative tumors, reducing the risk of death by 56 percent. The study suggests that chemotherapy has a greater impact on ER-negative patients than previously thought.
Researchers found that breast cancer patients who lose tau protein expression are twice as likely to have a good response to Taxol treatment. The discovery suggests that tumor tissue could be screened to predict which patients will respond to the chemotherapy, leading to improved treatment outcomes.
Researchers found that patients with basal-like and erbb2+ subgroups had the highest rates of pathological complete response to chemotherapy, while luminal tumors showed minimal response. The study suggests stratifying patients into molecular subgroups for more accurate treatment predictions.
The Advexin therapy, which delivers normal p53 genes to cancer cells, resulted in significantly smaller tumors and increased infiltration of T-lymphocytes, a key component of the immune system. After surgery, researchers found higher levels of normal p53 mRNA and an increase in the p53 protein, suggesting improved cancer response.
Researchers have developed a peptide vaccine that produces an immune response in 60% of patients with myeloid leukemia, resulting in complete molecular remission for three patients. The vaccine targets the PR1 peptide, which is overexpressed on leukemia cells, inducing immune T-cells to kill cancer cells while leaving normal cells intact.
A combination of two biologic agents, alemtuzumab and rituximab, with chemotherapy has shown a promising response rate of 55% in CLL relapse patients. Complete remission was achieved by 23% of patients, while leukemia levels were reduced by at least half in 35% of cases.
Researchers have discovered that BMS-354825 and AMN107 can effectively treat patients with leukemia who are resistant to Gleevec therapy. The studies found remarkable activity in these novel compounds, with high response rates and improved survival outcomes.
A new oral therapy, Zarnestra, has shown benefit in improving blood counts and preventing leukemia development in patients with myelodysplastic syndrome (MDS). The drug, a farnesyl transferase inhibitor, produces responses in about one-third of patients, offering hope for those at high-risk for developing acute myelogenous leukemia (AML).
A recent study by the University of Texas M. D. Anderson Cancer Center has found no link between taxane-based chemotherapies and pneumonitis in breast cancer patients. The research, led by Tse-Kuan Yu, analyzed 189 breast cancer patients who received either radiation therapy or chemotherapy followed by radiation.
Researchers have discovered a lethal attraction between HER2-positive breast cancer cells and organs, explaining why this form of breast cancer is so invasive. The study found that breast cancer cells overexpressing HER2 proteins also ramp up production of CXCR4, leading to a strong chemical signal that attracts them to specific organs.
Researchers found that activated STAT3 is necessary for skin cancer development, and inhibiting it can prevent tumor growth. A STAT3 inhibitor could potentially be used as a topical cream to treat sunburns or precancerous lesions.
Researchers engineered human mesenchymal stem cells to target tumors, delivering a therapeutic gene that inhibits cancer growth. The approach significantly improved survival of mice with breast and melanoma cancers.
A new protein, Rab25, has been associated with increased aggressiveness in both breast and ovarian cancers. Low levels of Rab25 protein expression were found to be linked to better clinical outcomes, with patients experiencing higher survival rates when tumors expressed low levels of the protein.
Researchers found that a combination of two novel agents - SCH66336 and IGFBP-3 - significantly reduced lung tumor size in mice implanted with human lung tumors. The treatment blocked multiple pathways important to cancer cell survival, showing tremendous potential for treating lung cancer patients.
Researchers at the University of Texas M. D. Anderson Cancer Center have discovered a critical molecular switch, GSK-3ß, that allows cancer cells to become mobile and move away from tumors. This discovery provides an anticancer strategy to pursue by boosting GSK-3ß activity, which can repress the ability of cancer to spread.